<DOC>
	<DOC>NCT00436670</DOC>
	<brief_summary>A Multi-center, Randomized, Placebo, Multi-Dose study to evaluate the efficacy of AMG 317 compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) symptom scores from baseline to week 12.</brief_summary>
	<brief_title>Phase II Study to Evaluate the Efficacy of AMG 317</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Males or females 18 to 65 years of age at the time of screening Baseline percent of predicted FEV1 ≥ 50% to ≤ 80% at screening At least 12% reversibility over baseline FEV1 with beta agonist inhalation, which can be demonstrated in the office or documented by medical record within the past 12 months Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000 µg/day fluticasone or equivalent. Stable ICS dose for ≥ 30 days before screening and dose expected to remain stable during treatment with investigational agent. Must have used ICS for at least the last 3 consecutive months before screening If receiving allergen immunotherapy, a stable dose for &gt; 3 months before screening and anticipated to remain stable for the duration of the study Positive to skin prick or RAST Ongoing asthma symptoms with ACQ score at screening and baseline ≥ 1.5 points Nonsmoker or exsmoker with &lt; 10 packyears (eg, 1 pack per day for 10 years) who stopped ≥ 1 year ago Acute asthma exacerbation requiring emergency room (ER) treatment or hospitalization within 3 months History of endotracheal intubation for asthmarelated exacerbation within 3 years of screening Respiratory illness within 4 weeks of screening History of chronic obstructive pulmonary disease (COPD) or other chronic pulmonary condition other than asthma Received longacting beta agonist, theophylline, inhaled anticholinergics, oral beta 2 agonists, or cromolyn therapeutics within 1 week of first runin visit. Leukotriene antagonists within 2 weeks before first runin visit Oral or parenteral corticosteroids within 6 weeks before first runin visit Live/attenuated vaccinations within 4 weeks of screening or during the study Any uncontrolled, clinically significant systemic disease (eg, chronic renal failure, uncontrolled hypertension, liver disease)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergy</keyword>
	<keyword>IL-13</keyword>
	<keyword>IL-4</keyword>
	<keyword>IL-4R</keyword>
</DOC>